Skip to Content

'
Nuhad K. Ibrahim

Present Title & Affiliation

Primary Appointment

Professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Research Interests

Vaccine in breast cancer, breast geriatric oncology, treatment of resistant breast cancer

Clinical Interests

Breast medical oncology

Education & Training

Degree-Granting Education

1980 Baghdad Medical College, Baghdad, Iraq, MD, Medicine
1975 American University of Beirut, Beirut, Lebanon, BS, Biology-Chemistry

Postgraduate Training

1991-1994 Postdoctoral Fellowship in Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, Dr. Richard Pazdur
1990-1991 PGYIII-Resident in Internal Medicine, St. Luke's-Roosevelt Hospital, New York, NY, Dr. Patrick Griffin
1988-1990 PGYI & PGYII-Resident in Internal Medicine, SUNY Health Science Center, Brooklyn, NY, Dr. Clark
1983-1986 Fellow in Clinical Hematology-Oncology, American University of Beirut Medical Center, Beirut, Lebanon, Dr. Samir Azzam
1981-1983 Resident in General Surgery, American University of Beirut Medical Center, Beirut, Lebanon, Dr. Samir Shehadeh
1980-1981 Straight Surgical Internship, American University of Beirut Medical Center, Beirut, Lebanon, Dr. Fouad Freyha

Board Certifications

1997 American Board of Medical Oncology
1994 American Board of Internal Medicine
1989 Federation Licensing Examination (FLEX)
1987 Foreign Medical Graduate Examination in the Medical Sciences (FMGEMS)

Experience/Service

Institutional Committee Activities

Member, Steering committee for the Sister Institution relationship between M. D. Anderson Cancer Center and the Faculty of Medicine and Medical Center of the American University of Beirut, 8/2007-present
Member, US-Middle East Breast Cancer Awareness & Research Committee, 2007-present
Member, Institutional Research Grants Program Study Section Review Committee for Clinical Translational and Population-Based Research Projects, 2005-present

Honors and Awards

2008-present Master of the American College of Ethical Physicians, American College of Ethical Physicians
2003-present Best Doctors in America

Selected Publications

Peer-Reviewed Original Research Articles
1. Kawano K, Efferson C, Babiera G, Meric-Bernstam F, Ibrahim N, Peoples GE, Humphreys RE, von Hofe E, and Murray JL. Increased potency of HER2/neu(776-790) MHC class II epitope linked to Ii-Key in stimulating T-cell responses and co-inducing CTL responses to E75 peptide in PMBC of breast cancer patients with HER2/neu-positive compared with HER2/neu-negative tumors. Cancer Immunol. In Press.
2. Shumway NM, Ibraim N, Ponniah S, Peoples GE, Murray JL. Therapeutic Breast Cancer Vaccines: A New Strategy for Early-Stage Disease. BioDrugs. In Press.
3. Estephan F, Valero V, Esteva F, Mejia J, Frey D, Ibrahim N. Phase I Study of Prolonged-infusion Gemcitabine Combined with Cyclophosphamide in Patients with Metastatic Carcinoma of the Breast: Tolerability of an Optimal Dose Schedule. Oncology 77(1):63-70, 6/2009. e-Pub 6/2009. PMID: 19556811.
4. Dawood S, Broglio K, Esteva FJ, Ibrahim NK, Kau SW, Islam R, Aldape KD, Yu TK, Hortobagyi GN, Gonzalez-Angulo AM. Defining prognosis for women with breast cancer and CNS metastases by HER2 status. Ann Oncol 19(7):1242-8, 7/2008. e-Pub 3/2008. PMID: 18334512.
5. Kaur H, Loyer EM, David CL, Sawaf H, DuBrow RA, Ibrahim NK. Radiologic findings in taxane induced colitis. Eur J Radiol 66(1):75-8, 4/2008. e-Pub 6/2007. PMID: 17553645.
6. Buzdar AU, Valero V, Ibrahim NK, Francis D, Broglio KR, Theriault RL, Pusztai L, Green MC, Singletary SE, Hunt KK, Sahin AA, Esteva F, Symmans WF, Ewer MS, Buchholz TA, Hortobagyi GN. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 13(1):228-33, 1/2007. PMID: 17200359.
7. Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, Mejia JA, Booser D, Theriault RL, Buzdar AU, Dempsey PJ, Rouzier R, Sneige N, Ross JS, Vidaurre T, Gomez HL, Hortobagyi GN, Pusztai L. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 24:4236-44, 9/2006. PMID: 16896004.
8. Motwani SB, Strom EA, Schechter NR, Butler CE, Lee GK, Langstein HN, Kronowitz SJ, Meric-Bernstam F, Ibrahim NK, Buchholz TA. The impact of immediate breast reconstruction on the technical delivery of postmastectomy radiotherapy. Int J Radiat Oncol Biol Phys 66:76-82, 9/2006. PMID: 16765534.
9. Altundag K, Ibrahim NK. Aromatase inhibitors in breast cancer: an overview. Oncologist 11(6):553-62, 6/2006. PMID: 16794235.
10. Ibrahim NK, Samuels B, Page R, Doval D, Patel KM, Rao SC, Nair MK, Bhar P, Desai N, Hortobagyi GN. Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol 23:6019-26, 9/2005. PMID: 16135470.
11. Green MC, Buzdar AU, Smith T, Ibrahim NK, Valero V, Rosales MF, Cristofanilli M, Booser DJ, Pusztai L, Rivera E, Theriault RL, Carter C, Frye D, Hunt KK, Symmans WF, Strom EA, Sahin AA, Sikov W, Hortobagyi GN. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 23(25):5983-92, 9/2005. PMID: 16087943.
12. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, Morandi P, Fan C, Rabiul I, Ross JS, Hortobagyi GN, Pusztai L. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11(16):5678-85, 8/2005. PMID: 16115903.
13. Pusztai L, Wagner P, Ibrahim N, Rivera E, Theriault R, Booser D, Symmans FW, Wong F, Blumenschein G, Fleming DR, Rouzier R, Boniface G, Hortobagyi GN. Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer 104(4):682-91, 8/2005. PMID: 15986399.
14. Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Pusztai L, Green MC, Arun BK, Giordano SH, Cristofanilli M, Frye DK, Smith TL, Hunt KK, Singletary SE, Sahin AA, Ewer MS, Buchholz TA, Berry D, Hortobagyi GN. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23:3676-85, 6/2005. PMID: 15738535.
15. Li Z, Ibrahim NK, Wathen JK, Wang M, Mante Menchu RP, Valero V, Theriault R, Buzdar AU, Hortobagyi GN. Colitis in patients with breast carcinoma treated with taxane-based chemotherapy. Cancer 101(7):1508-13, 10/2004. PMID: 15378497.
16. Ayers M, Symmans WF, Stec J, Damokosh AI, Clark E, Hess K, Lecocke M, Metivier J, Booser D, Ibrahim N, Valero V, Royce M, Arun B, Whitman G, Ross J, Sneige N, Hortobagyi GN, Pusztai L. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 22(12):2284-93, 6/2004. PMID: 15136595.
17. Pusztai L, Mendoza TR, Reuben JM, Martinez MM, Willey JS, Lara J, Syed A, Fritsche HA, Bruera E, Booser D, Valero V, Arun B, Ibrahim N, Rivera E, Royce M, Cleeland CS, Hortobagyi GN. Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine 25(3):94-102, 2/2004. PMID: 14698135.
18. Morandi P, Rouzier R, Altundag K, Buzdar A, Theriault R, Arun B, Booser D, Cristofanilli M, Esteva F, Gonzalez-Angulo A, Giordano S, Green M, Gwyn K, Ibrahim N, Murray J, Pusztai L, Rivera E, Thomas E, Valero V, Walters R, Bast R, Bevers T, Brewster A, Buchholz T, McNeese M, Strom E, Hortobagyi GN. The Role of Aromatase Inhibitors in the Adjuvant Treatment of Breast Cancer: MD Anderson Cancer Center Evidence Based Approach. Cancer 101 (7):1482-1489, 2004.
19. Trent JC, Valero V, Booser DJ, Esparza-Guerra LT, Ibrahim N, Rahman Z, Vernillet L, Patel S, David CL, Murray JL, Cristofanilli M, Hortobagyi GN. A Phase I study of docetaxel plus cyclophosphamide in solid tumors followed by a Phase II study as first-line therapy in metastatic breast cancer. Clin Cancer Res 9(7):2426-34, 7/2003. PMID: 12855614.
20. Symmans WF, Ayers M, Clark EA, Stec J, Hess KR, Sneige N, Buchholz TA, Krishnamurthy S, Ibrahim NK, Buzdar AU, Theriault RL, Rosales MF, Thomas ES, Gwyn KM, Green MC, Syed AR, Hortobagyi GN, Pusztai L. Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma. Cancer 97(12):2960-71, 6/2003. PMID: 12784330.
21. Kantarjian HM, Gandhi V, Kozuch P, Faderl S, Giles F, Cortes J, O'Brien S, Ibrahim N, Khuri F, Du M, Rios MB, Jeha S, McLaughlin P, Plunkett W, Keating M. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol 21(6):1167-73, 3/2003. PMID: 12637486.

Last updated: 9/17/2009